Novel high-Throughput screen identifies an HIV-1 reverse transcriptase inhibitor with a unique mechanism of action

Biochemical Journal

Volumn 462, Issue 3, 2014, Pages 425-432

  Sheen, Chih Wei ^a   Alptürk, Onur ^a   Sluis Cremer, Nicolas ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Excision; High throughput screen; Inhibitor; Reverse transcriptase; Zidovudine

Indexed keywords

APEX 57219; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; [3,3' [(3 CARBOXY 4 OXO 2,5 CYCLOHEXADIEN 1 YLIDENE)METHYLENE]BIS[6 HYDROXYBENZOIC ACID]];

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME INHIBITION; FORSTER RESONANCE ENERGY TRANSFER HIGH THROUGHPUT SCREENING ASSAY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL NOISE RATIO; VIRUS REPLICATION;

FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH-THROUGHPUT SCREENING ASSAYS; HIV REVERSE TRANSCRIPTASE; KINETICS; REVERSE TRANSCRIPTASE INHIBITORS; SALICYLATES; VIRUS REPLICATION;

EID: 84907344278     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20140365     Document Type: Article

References (29)

1. Le Grice, S. F. (2012) Human immunodeficiency virus reverse transcriptase: 25 years of research, drug discovery, and promise. J. Biol. Chem. 287, 40850-40857.
2. Goody, R. S., Müller, B. and Restle, T. (1991) Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo. FEBS Lett. 291, 1-5.
3. Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A. and Steitz, T. A. (1992) Crystal structure at 3.5A° resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256, 1783-1790.
4. Menéndez-Arias, L. (2013) Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res. 98, 93-120.
5. Richman, D. D. (1991) AZT resistance in isolates of HIV. Immunodefic. Rev. 2, 315-318.
6. Whitcomb, J. M., Parkin, N. T., Chappey, C., Hellmann, N. S. and Petropoulos, C. J. (2003) Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J. Infect. Dis. 188, 992-1000.
7. Borroto-Esoda, K., Parkin, N. and Miller, M. D. (2007) A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine. Antivir. Chem. Chemother. 18, 297-300.
8. Meyer, P. R., Matsuura, S. E., So, A. G. and Scott, W. A. (1998) Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc. Natl. Acad. Sci. U.S.A. 95, 13471-13476.
9. Meyer, P. R., Matsuura, S. E., Mian, A. M., So, A. G. and Scott, W. A (1999) A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4, 35-43
10. Arion, D., Kaushik, N., McCormick, S., Borkow, G. and Parniak, M. A. (1998) Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′- deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37, 15908-15917.
11. Ray, A. S., Murakami, E., Basavapathruni, A., Vaccaro, J. A., Ulrich, D., Chu, C. K., Schinazi, R. F. and Anderson, K. S. (2003) Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. Biochemistry 42, 8831-8841.
12. Borkow, G., Arion, D., Wainberg, M. A. and Parniak, M. A. (1999) The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3′-azido-3′-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 43, 259-263.
13. Basavapathruni, A., Bailey, C. M. and Anderson, K. S. (2004) Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs. J. Biol. Chem. 279, 6221-6224.
14. Radzio, J. and Sluis-Cremer, N. (2008) Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision. Mol. Pharmacol. 73, 601-606.
15. Song, Y., Chan, J. M., Tovian, Z., Secrest, A., Nagy, E., Krysiak, K., Bergan, K., Parniak, M. A. and Oldfield, E. (2008) Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3′-azido, 3′-deoxythymidine: a QSAR investigation. Bioorg. Med. Chem. 16, 8959-8967.
16. Le Grice, S. F., Cameron, C. E. and Benkovic, S. J. (1995) Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase. Methods Enzymol. 262, 130-144.
17. Herman, B. D. and Sluis-Cremer, N. (2013) Transient kinetic analyses of the ribonuclease H cleavage activity of HIV-1 reverse transcriptase in complex with efavirenz and/or a β-thujaplicinol analogue. Biochem. J. 455, 179-184.
18. Macarrón, R. and Hertzberg, R. P. (2002) Design and implementation of high throughput screening assays. In Methods in Molecular Biology (Janzen W. P., ed) 190, pp. 1-29, Humana Press Totowa.
19. Zhang, J. H., Chung, T. D. and Oldenburgh, K. R. (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 27-32.
20. Nissley, D. V., Radzio, J., Ambrose, Z., Sheen, C. W., Hamamouch, N., Moore, K. L., Tachedjian, G. and Sluis-Cremer, N. (2007) Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT. Biochem. J. 404, 151-157.
21. Shi, C. and Mellors, J. W. (1997) A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 41, 2781-2785.
22. Xu, H., Franks, T., Gibson, G., Huber, K., Rahm, N., De Castillia, C. S., Luban, J., Aiken, C., Watkins, S., Sluis-Cremer, N. and Ambrose, Z. (2013) Evidence for biphasic uncoating during HIV-1 infection from a novel imaging assay. Retrovirology 10, 70.
23. Julias, J. G., McWilliams, M. J., Sarafianos, S. G., Arnold, E. and Hughes, S. H. (2002) Altering the RNase H primer grip of human immunodeficiency virus reverse transcriptase modifies cleavage specificity. Biochemistry 41, 4856-4865.
24. Abbondanzieri, E. A., Bokinsky, G., Rausch, J. W., Zhang, J. X., Le Grice, S. F. and Zhuang, X. (2008) Dynamic binding orientations direct activity of HIV reverse transcriptase. Nature 453, 184-189.
25. Liu, S., Abbondanzieri, E. A., Rausch, J. W., Le Grice, S. F. and Zhuang, X. (2008) Slide into action: dynamic shuttling of HIV reverse transcriptase on nucleic acid substrates. Science 322, 1092-1097.
26. Radzio, J. and Sluis-Cremer, N. (2011) Subunit-specific mutational analysis of residue N348 in HIV-1 reverse transcriptase. Retrovirology 8, 69.
27. Boyer, P. L., Sarafianos, S. G., Arnold, E. and Hughes, S. H. (2001) Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J. Virol. 75, 4832-4842.
28. Sarafianos, S. G., Clark, Jr, A. D., Das, K., Tuske, S., Birktoft, J. J., Ilankumaran, P., Ramesha, A. R., Sayer, J. M., Jerina, D. M., Boyer, P. L. et al. (2002) Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. EMBO J. 21, 6614-6624.
29. Rescifina, A., Zagni, C., Varrica, M. G., Pistarà, V. and Corsaro, A. (2014) Recent advances in small organic molecules as DNA intercalating agents: synthesis, activity, and modeling. Eur. J. Med. Chem. 74C, 95-115.